After the FTC filed a lawsuit in September, accusing the three major pharmacy benefit managers of anticompetitive rebating practices related to insulin, the defendants reversed roles and became plaintiffs. In November, they countersued the agency, arguing that its lawsuit is unconstitutional.
The post The Big 3 PBMs are Countersuing the FTC. Does Their Argument Have Any Teeth? appeared first on MedCity News.
